We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Altamira Therapeutics Ltd (CYTO) USD0.002

Sell:$0.73 Buy:$0.75 Change: $0.0291 (3.83%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.73
Buy:$0.75
Change: $0.0291 (3.83%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.73
Buy:$0.75
Change: $0.0291 (3.83%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Contact details

Address:
Clarendon House, 2 Church Street
HAMILTON
6300
Bermuda
Telephone:
+41 (61) 2011350
Website:
https://aurismedical.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYTO
ISIN:
BMG0360L1349
Market cap:
$1.66 million
Shares in issue:
2.24 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Bermuda
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.